Durrant updated investors on the opportunity within its clinical collaboration with Kite, a company belonging to Gilead Sciences Inc (NASDAQ:GILD), along with Humanigen's efforts to develop its own CAR-T cells, a new approach to cancer therapy involving altered T cells.
Humanigen updates on its clinical collaboration with Gilead Sciences subsidiary, Kite
Quick facts: Humanigen, Inc.
Price: - -
Market Cap: -
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Humanigen, Inc. named herein, including the promotion by the Company of Humanigen, Inc. in any Content on the Site, the Company receives from...FOR OUR FULL DISCLAIMER CLICK HERE